Finance

Lists
Why is GOSS down 8.04%?
Dive Deeper
GOSS:NASDAQ
Gossamer Bio Inc
$8.98
-8.04%
(-0.78) 1D
Oct 14, 2:49:26 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GOSS...
Open
$9.59
High
$9.64
Low
$8.93
Mkt. cap
54.89M
Avg. vol.
2.61M
Volume
229.78K
52-wk high
$309.20
52-wk low
$8.93
EPS
-$45.04
Beta
2.21
Shares outstanding
6.11M
No. of employees
161
Open
$9.59
High
$9.64
Low
$8.93
Mkt. cap
54.89M
Avg. vol.
2.61M
Volume
229.78K
52-wk high
$309.20
52-wk low
$8.93
EPS
-$45.04
Beta
2.21
Shares outstanding
6.11M
No. of employees
161
News stories
From web sources and news partners
About Gossamer Bio Inc
CEO-
Employees161
Founded2015
Headquarters-
SectorBiotechnology
Websitegossamerbio.com
Analyst ratings
Based on 5 analysts giving stock ratings to GOSS in the past 3 months
Hold
Buy
2
Hold
2
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for GOSS in the last 3 months.
Highest
Current $8.98
$90.00 (+902.79%)
Average
$68.10 (+658.77%)
Lowest
$22.40 (+149.58%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
09/23/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$90.00
+902.8%
09/21/2026
Laura Chico
Wedbush
Hold
Maintained
$80.00
+791.4%
08/14/2026
Eliana Merle
Barclays
Sell
Maintained
$22.40
+149.6%
07/28/2026
Joseph Schwartz
Leerink Partners
Buy
Upgraded
$80.00
+791.4%
07/27/2026
Olivia Brayer
Cantor Fitzgerald
Hold
Downgraded
-
-
03/20/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$15.00
+67.1%
03/18/2026
Andreas Argyrides
Oppenheimer
Buy
Maintained
$3.00
-66.6%
03/05/2026
Paul Choi
Goldman Sachs
Hold
Downgraded
$0.50
-94.4%
02/24/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
-$8.17 / -$9.99
+18.23%beat
Revenue / Est. (USD)
9.24M / 4.35M
+112.14%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.29M
13.80M
16.96M
9.24M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
45.54M
48.94M
43.08M
26.41M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.39M
10.90M
18.75M
8.90M
Operating expense
54.93M
59.84M
61.82M
35.31M
Total operating expenses
54.93M
59.84M
61.82M
35.31M
Operating income
-41.64M
-46.04M
-44.87M
-26.07M
Other non operating income
2.95M
-3.46M
603.00K
1.56M
EBT including unusual items
-48.22M
-47.33M
-46.66M
16.90M
EBT excluding unusual items
-40.74M
-51.80M
-46.66M
-26.95M
Income tax expense
-
-88.00K
-
-
Effective tax rate
-
0.19%
-
-
Other operating expenses
-
-
-
-
Net income
-48.22M
-47.24M
-46.66M
16.90M
Net profit margin
-362.73%
-342.33%
-275.22%
182.94%
Earnings per share
-16.80
-16.80
-16.00
-8.17
Interest and investment income
687.00K
447.00K
354.00K
268.00K
Interest expense
-2.75M
-2.75M
-2.76M
-2.70M
Net interest expenses
-2.06M
-2.30M
-2.40M
-2.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.63M
-46.03M
-44.86M
-26.07M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps